Metformin administration has recently emerged as a candidate strategy for the prevention of head and neck squamous cell carcinoma (HNSCC). However, the intricate relationship between genetic alterations in HNSCC and metformin sensitivity is still poorly understood, which prevents the stratification of patients, harboring oral premalignant lesions that may benefit from the chemopreventive activity of metformin. In this study, we investigate the impact of prevalent mutations in HNSCC on response to metformin. Notably, we found that the expression of oncogenic HRAS mutants confers resistance to metformin in isogenic HNSCC cell systems, and that HNSCC cells harboring endogenous HRAS mutations display limited sensitivity to metformin. Remarkably, we found that metformin fails to reduce activation of the mTOR pathway in HRAS oncogene-expressing HNSCC cells in vitro and in vivo, correlating with reduced tumor suppressive activity. Mechanistically, we found that this process depends on the ability of HRAS to enhance glycolytic metabolism, thereby suppressing the requirement for oxidative phosphorylation to maintain the cellular energetic balance. Overall, our study revealed that HNSCC cells with oncogenic HRAS mutations exhibit diminished metformin sensitivity, thus shedding light on a potential mechanism of treatment resistance. This finding may also help explain the limited clinical responses to metformin in cancers with RAS mutations. Ultimately, our study underscores the importance of understanding the impact of the genetic landscape in tailoring precision cancer-preventive approaches in the context of HNSCC and other cancers that are characterized by the presence of a defined premalignant state, and therefore, are amenable to cancer interception strategies. Prevention Relevance: Our findings highlight the challenges of using metformin for cancer prevention in RAS-mutant cancers, where elevated glycolysis may reduce drug efficacy. This underscores the need to explore metformin’s potential in early, premalignant stages, before metabolic shifts render it less effective.
Head and neck squamous cell carcinoma (HNSCC) is among the 10 most common cancers worldwide and is associated with high morbidity and poor survival. Diminished HNSCC outcomes are often related to delayed diagnosis and treatment of occult progression of premalignant lesions, underscoring the need for effective and low-risk chemoprevention strategies. In this regard, metformin has shown promising clinical activity for HNSCC prevention. In this study, we performed a genome-wide CRISPR/Cas9 screen of metformin-treated HNSCC cells and identified the activation of PKA signaling as the top resistance pathway. We show that metformin mediates PKA activation in HNSCC cells and that PKA inhibition, when combined with metformin treatment, synergistically inhibits HNSCC growth. We found that metformin-induced PKA activation is mediated by a prostaglandin E2 autocrine loop, which can be blocked using cyclooxygenase-2 (COX2) inhibitors. Importantly, COX2 inhibition using nonsteroidal anti-inflammatory drugs (NSAID) combined with metformin treatment synergistically inhibits HNSCC cell growth and prevents the progression of oral premalignant lesions into invasive HNSCC in a model of tobacco-driven oral carcinogenesis. Together, these findings demonstrate that metformin and NSAID combination therapy may represent a promising therapeutic strategy for HNSCC chemoprevention. Prevention Relevance: Our findings reveal that using metformin for head and neck cancer chemoprevention leads to compensatory activation of a PKA-driven resistance mechanism that can be blocked by cotreatment with NSAIDs. These findings provide a rationale for combining metformin with NSAIDs as a precision head and neck cancer chemoprevention strategy.
Tumor initiation represents the initial step in tumorigenesis during which normal progenitor cells undergo cell fate transition to cancer. Most studies investigating cancer-driving mechanisms in solid tumors rely on analyses of established malignant lesions, and thus cannot directly capture processes underlying the reprogramming of normal progenitor cells into cancer cells. Here, using spatiotemporally controlled oncogene expression in a genetically engineered system we demonstrate that concomitant YAP activation and HPVE6-E7-mediated inhibition of tumor suppressive pathways is sufficient to rapidly reprogram oral epithelial progenitor cells (OEPCs) into cancer stem cells (CSCs). Single cell analyses of these nascent CSCs revealed hallmark transcriptional programs driving tumor initiation. Importantly, these CSC-enriched expression signatures distinguish normal tissue from malignant head and neck tumors and are associated with poor patient survival. Elucidating mechanisms underlying OEPC to CSC reprogramming may offer new insights to halt the conversion of premalignant cells into invasive carcinoma. HIGHLIGHTS YAP and HPVE6-E7 reprogram oral epithelial progenitor cells into cancer stem cells. Single cell analyses reveal the transcriptional architecture of tumor initiation. CSC transcriptional programs distinguish normal tissue from carcinoma. CSC signatures are associated with poor head and neck cancer survival.
18 December 2025 in Journal of Biological Chemistry
Cyclooxygenase-2 (COX-2/PTGS2) is an inducible enzyme central to inflammatory responses, and its expression is tightly regulated. Elevated intracellular cAMP levels are known to stimulate COX-2 expression. However, the precise mechanism by which protein kinase A (PKA), the primary cAMP effector, mediates this process remains elusive. In this study, we investigated the role of PKA in regulating COX-2 expression in macrophages. We found that PKA activity is essential for COX-2 expression, primarily through a post-transcriptional mechanism that enhances COX-2 mRNA stability. This effect is mediated by the interaction between PKA and the RNA-binding proteins HuR (ELAVL1) and TTP (tristetraprolin/ZFP36). Specifically, we observed that the catalytic subunit of PKA directly interacts with HuR, a well-established COX-2 mRNA stabilizer. PKA activation increased HuR binding to COX-2 mRNA, and pharmacological inhibition of HuR abrogated COX-2 expression in macrophages stimulated with PGE2 and IL-1β. Furthermore, PKA stimulates the phosphorylation of TTP, an mRNA-destabilizing protein, thereby reducing its binding to the COX-2 transcript. We propose that PKA enhances COX-2 expression by interacting with HuR, maintaining proximity to COX-2 mRNA, and protecting it from TTP-mediated destabilization. Our findings reveal a mechanistic link between PKA activity and COX-2 mRNA stability through HuR and TTP, highlighting the role of RNA-binding proteins as novel effectors of PKA signaling in post-transcriptional regulation.
Supplementary Figure 5. Combination of metformin with NSAIDs, which inhibit COX2, enhances the inhibition of HNSCC cell growth in vitro. (Related to Figure 3)